Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 5/20 | 0.39 |
| ▸ | HRH1 | P35367 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648708 | 0.93 | CHRM4 (0.39) | CCR3HRH1KCNH2MAOAMAOB | |
| SCHEMBL4403491 | 0.88 | MAOA (0.53) | CCR3HRH1KCNH2MAOAMAOB | |
| SCHEMBL13845633 | 0.87 | MAOB (0.44) | CCR3HRH1KCNH2MAOAMAOB | |
| SCHEMBL4402675 | 0.87 | MAOA (0.43) | CCR3HRH1KCNH2MAOAMAOB | |
| SCHEMBL4401700 | 0.84 | LMNA (0.48) | KMT2AMEN1 | |
| SCHEMBL4402665 | 0.84 | MAOB (0.42) | CCR3HRH1KCNH2MAOAMAOB | |
| SCHEMBL4403522 | 0.83 | CHRNB2 (0.43) | MAOAMAOBKMT2AMEN1HRH3 | |
| SCHEMBL4403502 | 0.83 | ADRB2 (0.46) | CCR3KCNH2MAOAMAOBMCHR1 | |
| SCHEMBL4403510 | 0.82 | AR (0.45) | CCR3HRH1KCNH2MAOAMAOB | |
| SCHEMBL15171495 | 0.82 | MAOA (0.49) | CCR3HRH1KCNH2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9409884-B2 | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9174964-B2 | AMPK-activating piperidinyloxy-substituted 2,3-dihydro-1H-indene-1-amine compounds and pharmaceutical compositions including the same | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140378429-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140323460-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | MIDCAP FINANCIAL TRUST | 2014-10-30 | — | — | US | disclosed |
| US-8796254-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140051673-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8569340-B2 | AMPK-activating piperidinyloxypyiridine carboxamide and sulfonamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120115838-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | CCR3 3758/4885HRH1 3680/4885KCNH2 3255/4885 |
| US-20140323460-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | CCR3 3758/4885HRH1 3680/4885KCNH2 3255/4885 |
| US-20140051673-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | PRKAA1, PRKAA2, PRKAG1 | CCR3 4213/4885HRH1 3674/4885KCNH2 3860/4885 |
| US-20120115838-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | PRKAA1, PRKAA2, PRKAG1 | CCR3 4213/4885HRH1 3674/4885KCNH2 3860/4885 |
| US-20140378429-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them | CPT2, SHMT2, CS | CCR3 3598/4885HRH1 3380/4885KCNH2 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.